Harmony Biosciences Q3 2023 EPS $0.97 May Not Compare To $0.65 Estimate, Revenue $160.268M May Not Compare To $148.608M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences reported Q3 2023 earnings per share (EPS) of $0.97, which may not compare to the estimated $0.65. The company's revenue was $160.268M, potentially surpassing the estimated $148.608M.
October 31, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences' Q3 2023 earnings and revenue may have outperformed estimates, which could positively impact the company's stock.
Harmony Biosciences reported higher than expected earnings and revenue for Q3 2023. This outperformance could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100